Intraperitoneal photodynamic therapy for peritoneal carcinomatosis and sarcomatosis

Stephen M. Hahn; Douglas L. Fraker; Timothy C. Zhu; Arjun G. Yodh; Carmen E. Rodriguez; Debbie Smith; Ann Currens; Eli Glatstein M.D.

doi:10.1117/12.379893

29 March 2000 Intraperitoneal photodynamic therapy for peritoneal carcinomatosis and sarcomatosis

Stephen M. Hahn, Douglas L. Fraker, Timothy C. Zhu, Arjun G. Yodh, Carmen E. Rodriguez, Debbie Smith, Ann Currens, Eli Glatstein M.D.

Author Affiliations +

Proceedings Volume 3909, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX; (2000) https://doi.org/10.1117/12.379893
Event: BiOS 2000 The International Symposium on Biomedical Optics, 2000, San Jose, CA, United States

Abstract

The preliminary results of an ongoing Phase II trial of Photofrin-mediated intraperitoneal PDT (IP PDT) are presented. The clinical endpoints of this trial are to determine the response rates of patients with carcinomatosis and sarcomatosis to IP PDT and to document the toxicities of IP PDT in a defined patient population. Photofrin, 2.5 mg/kg, was administered intravenously 48 hours prior to debulking surgery and light delivery, 57 patients with ovarian cancer, gastrointestinal cancers, and sarcomas were enrolled. 44 patients received Photofrin and received light treatment. 39 patients are valuable for response. 8 of 39 patients had a complete radiographic response to IP PDT 3 months after treatment. 3 patients are alive without evidence of disease 6, 6 and 9 months after treatment. 1 patient is alive and has no evidence of intra-abdominal disease but has developed lung metastases. Toxicities include post-operative fluid shifts, hypotension, hydronephrosis, pleural effusions, enteric fistula, transient liver function test elevation, thrombocytopenia, and wound dehiscence. Toxicity is related to pre-operative tumor bulk and to the extensiveness of surgery required. IP PDT is feasible and leads to an initial clinical response rate of 25 percent in patients with incurable peritoneal carcinomatosis and sarcomatosis.

Citation Download Citation

Stephen M. Hahn, Douglas L. Fraker, Timothy C. Zhu, Arjun G. Yodh, Carmen E. Rodriguez, Debbie Smith, Ann Currens, and Eli Glatstein M.D. "Intraperitoneal photodynamic therapy for peritoneal carcinomatosis and sarcomatosis", Proc. SPIE 3909, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX, (29 March 2000); https://doi.org/10.1117/12.379893

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available